Data mining analysis for the investigation of clinical features of chronic hepatitis C

慢性丙型肝炎临床特征调查的数据挖掘分析

• 批准号: 20590768
• 负责人: KUROSAKI Masayuki
• 金额: $ 3万
• 依托单位: University of Yamanashi
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20590768/
• 关键词: データ・マイニング; C型肝炎; 肝がん; インターフェロン; 個別化診療; データマイニング; C型慢性肝炎

We have analyzed factors that are predictive of response to peg-interferon plus ribavirin in chronic hepatitis C using data mining method. We found that hepatic steatosis, lower LDL-cholesterol level, higher glucose level and higher GGT level was predictive of poor virological response during the early treatment period. The HCV sequences in the ISDR and Core 70 was predictors of response independently of other factors. In 2009, a SNP near the IL28B was found to be most closely associated with the response to interferon therapy. We found that while IL28B was associated with the probability of viral decline, ISDR was a predictor of SVR independently of IL28B since ISDR was related to relapse of hepatitis. In the search for the factors associated with HCC development, lower albumin, higher FIB-4 index, hepatic steatosis and hyperglycemia was identified as a significant predictor. Hyperglycemia and hepatic steatosis was related to HCC development independent of liver fibrosis. Whether thee metabolic features could be the target for therapeutic intervention to reduce the incidence of HCC awaits further investigation.

我们使用数据挖掘方法分析了慢性丙型肝炎患者对聚乙二醇干扰素联合利巴韦林治疗反应的预测因素。我们发现肝脂肪变性、低密度脂蛋白胆固醇水平降低、血糖水平升高和GGT水平升高是早期治疗期间病毒学应答差的预测因素。ISDR和Core 70中的HCV序列是独立于其他因素的应答预测因子。2009年，人们发现IL 28 B附近的SNP与干扰素治疗的反应最密切相关。我们发现，虽然IL 28 B与病毒下降的可能性有关，但ISDR是独立于IL 28 B的SVR的预测因子，因为ISDR与肝炎复发有关。在寻找与HCC发展相关的因素时，低白蛋白、高FIB-4指数、肝脂肪变性和高血糖被确定为重要的预测因子。高脂血症和肝脂肪变性与肝细胞癌的发展相关，而与肝纤维化无关。这些代谢特征是否可以作为治疗干预的目标以降低HCC的发病率有待进一步研究。

项目成果

The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

• DOI: 10.1016/j.jhep.2007.12.025
• 发表时间: 2008-05-01
• 期刊: JOURNAL OF HEPATOLOGY
• 影响因子: 25.7
• 作者: Kurosaki, Masayuki;Matsunaga, Kotaro;Izumi, Namiki
• 通讯作者: Izumi, Namiki

Association of IL 28B polymorphism with response topegylated-interferon alpha plus ribavirin combination therapy in patients with chronic genotype 2 hepatitis C

IL 28B 多态性与慢性基因 2 型丙型肝炎患者的拓扑乙二醇化干扰素 α 加利巴韦林联合治疗反应的相关性

• 发表时间: 2011
• 期刊: J Medical Virol
• 作者: Nakagawa M;et. Al
• 通讯作者: et. Al

A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis

• DOI: 10.1111/j.1872-034x.2009.00607.x
• 发表时间: 2010-03-01
• 期刊: HEPATOLOGY RESEARCH
• 影响因子: 4.2
• 作者: Kurosaki, Masayuki;Matsunaga, Kotaro;Izumi, Namiki
• 通讯作者: Izumi, Namiki

Prediction of Response to Pegylated-Interferon for Chronic Hepatitis C : Impact of SNPs near the IL28B gene and Mutations in the ISDR of HCV Revealed by Data Mining Analysis.

预测慢性丙型肝炎对聚乙二醇化干扰素的反应：数据挖掘分析揭示的 IL28B 基因附近的 SNP 和 HCV ISDR 突变的影响。

• 发表时间: 2010
• 作者: Kurosaki M;et al.
• 通讯作者: et al.

Peginterferon/ribavirin併用療法の治療前効果予測データマイニング解析による予測アルゴリズムの構築と検証

聚乙二醇干扰素/利巴韦林联合治疗的治疗前效果预测 使用数据挖掘分析构建和验证预测算法

• 发表时间: 2008
• 作者: 小船雅義;井山諭;迦藤淳二;黒崎雅之
• 通讯作者: 黒崎雅之